Navigation Links
Actos Cut Risk of Prediabetes Becoming Diabetes in Study
Date:3/23/2011

By Serena Gordon
HealthDay Reporter

WEDNESDAY, March 23 (HealthDay News) -- Researchers report that taking the diabetes drug Actos helped people who had prediabetes avoid getting type 2 diabetes.

"Pioglitazone [Actos] was extremely effective in preventing diabetes," said study author Dr. Ralph DeFronzo, deputy director of the Texas Diabetes Institute and chief of the diabetes division at the University of Texas Health Science Center in San Antonio. The actual reduction in risk was 72 percent.

"The reason that people go from prediabetes to diabetes is that the insulin-producing beta cells fail. By the time someone is diagnosed with prediabetes, they may have lost 70 percent to 80 percent of beta cell function. Pioglitazone improves how the body responds to insulin and protects the beta cells from failing," he explained.

The study, which was funded by the drug's manufacturer, Takeda Pharmaceuticals, is published in the March 24 issue of the New England Journal of Medicine.

The U.S. Centers for Disease Control and Prevention estimates that as many as 79 million Americans may have prediabetes, with about half of those cases in people older than 65. Changes in lifestyle -- losing 5 percent of body weight and exercising at least 30 minutes a day most days of the week -- often helps prevent prediabetes from turning into type 2 diabetes. However, most people aren't able to maintain those lifestyle changes over the long term, DeFronzo noted.

After diet and exercise, the next recommended therapy is a drug called metformin. "Metformin can reduce the risk of diabetes by about 30 percent," said Dr. Vivian Fonseca, president-elect of medicine and science for the American Diabetes Association.

The current study was designed to assess whether or not Actos was more effective than a placebo in reducing the risk of developing type 2 diabetes.

The study included 602 people over the age of 18 who had been diagnosed with prediabetes. All of the study participants had a body-mass index over 25, which meant that they were either overweight or obese.

Study participants were randomly assigned to receive either 45 milligrams of pioglitazone daily or a placebo. Each participant had fasting blood sugar tests done quarterly, and glucose tolerance testing done annually to check for diabetes. The average follow-up time was 2.4 years.

The average rate that type 2 diabetes developed in the study participants was 2.1 percent for the pioglitazone group and 7.6 percent in the placebo group. And, nearly half of those on pioglitazone returned to normal blood sugar levels, while just 28 percent of those in the placebo group did.

In addition, people in the pioglitazone group averaged lower blood pressure, and had reduced inta-media carotid thickening (a measure of plaque build-up in the carotid artery). Levels of "good" HDL cholesterol also increased in the pioglitazone group.

The news wasn't all good, however. The people in the pioglitazone group experienced more adverse events (151 vs. 121) and gained an average of about nine pounds, and experienced more fluid retention (edema), than people taking the placebo. (The U.S. Food and Drug Administration has warned that, as with other thiazolidinediones, pioglitazone can cause fluid retention, potentially leading to or exacerbating heart failure.)

However, DeFronzo said that the weight gain was somewhat paradoxical because the drug causes fat deposits in superficial tissues, and moves fat out of the liver, heart and abdomen, where it's more detrimental to your health.

Fonseca said the results from this study look excellent, but added, "One has to consider the lack of knowledge of long-term safety in a population that's already at risk of disease."

"People with prediabetes should seriously think about healthy lifestyle changes first, and if you can't achieve a healthy lifestyle, you should talk to your doctor about medical treatments," said Fonseca. He said the American Diabetes Association recommends metformin as the first-line treatment if lifestyle changes don't work. Metformin is much cheaper than Actos because it's available as a generic. In addition, he said, it's been available for decades so its side effect profile is well-known.

Although Fonseca was not involved in this study, he disclosed that he is a paid consultant to Takeda Pharmaceuticals as a member of its new drug data safety monitoring board.

DeFronzo, however, recommended initiating drug treatment and lifestyle changes at the same time in people who are at a high risk of developing type 2 diabetes. People at high risk of type 2 diabetes include people with a family history of diabetes, women who've had gestational diabetes, Hispanics, blacks or Native Americans, people with metabolic syndrome, people who are overweight or obese, and those who have higher levels of glucose intolerance, he said.

"If someone is at high risk, then I would, in addition to trying to get them to lose weight and exercise, recommend medication, and personally, I favor pioglitazone. If you can really lose 30 pounds -- or whatever it is you need to lose -- then you might be able to discontinue the medication," said DeFronzo. "It's important to intervene early, rather than later, to save beta cell function."

More information

Learn more about prediabetes from the American Diabetes Association.

SOURCES: Ralph A. DeFronzo, deputy director, Texas Diabetes Institute, and chief, diabetes division, University of Texas Health Science Center, San Antonio; Vivian Fonseca, M.D., president-elect, medicine and science, American Diabetes Association; March 24, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Diabetes Drugs Avandia, Actos Tied to Fractures in Women
2. Think Youre Lactose Intolerant? Maybe Not
3. Soyfoods Aid Those With Lactose Intolerance
4. Avoiding Dairy Due to Lactose Intolerance is Unnecessary in Most Cases and May Pose Diet and Health Risks, Concludes National Institutes of Health Consensus Development Conference Panel
5. Abbey Color Inc. and Mexicana de Extractos International, S.A. de C.V. Announce Joint Venture Abbymex
6. People with prediabetes not taking adequate precautions to avoid diabetes
7. Having Prediabetes May Not Kick-Start Prevention Efforts
8. 105 Million in U.S. Have Diabetes or Prediabetes, CDC Says
9. Youth Baseball Injuries Becoming More Common
10. SensiblyCelibate.com Encourages Relationships Without the Pressures of Becoming Intimate Too Prematurely
11. With Cosmetic Surgery Becoming More Common, Ft. Lauderdale Doctor says Choosing a Board Certified Plastic Surgeon is Important for Safe, Natural-Looking Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Actos Cut Risk of Prediabetes Becoming Diabetes in Study
(Date:6/27/2017)... ... June 27, 2017 , ... Nearly 70 ... survey data released today by the American Society for Dermatologic Surgery ... the percentage of consumers considering a cosmetic medical procedure has doubled since 2013. ...
(Date:6/27/2017)... ... June 27, 2017 , ... Building on the ... Louisiana became the sixth state to pass legislation which ensures that children can ... signature, Louisiana joins the states of Alabama, Arizona, Florida, Utah and Washington who ...
(Date:6/27/2017)... York, NY (PRWEB) , ... June 27, 2017 ... ... and marketing experts to contribute to an upcoming case studies guidebook. This guidebook ... her organization. , This book will include articles, case studies and how-to’s that ...
(Date:6/27/2017)... ... June 27, 2017 , ... Today, June 27th is PTSD Awareness Day. ... than 20% will receive adequate care due to lack of effective treatments, fear of ... at all. And left untreated, veterans are at an increased risk for self-destructive behavior, ...
(Date:6/26/2017)... ... 2017 , ... Antoine Dental Center is now offering various types of dental implants ... as a support for prosthetic teeth, such as crowns, bridges, or dentures. An implant is ... sturdy, lasting new root for the tooth. , Several types of dental implants are ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... Datascope Corp. is voluntarily performing a worldwide field correction of certain Intra-Aortic Balloon ... ... CS100i ... 0998-UC-0446HXX; 0998-UC-0479HXX 0998-00-3013-XX;  0998-UC-3013-XX 0998-00-3023-XX;  ... This field correction also applies to any System 98 ...
(Date:6/13/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... U.S. Food and Drug Administration (FDA) has notified the Company ... its Zhejiang, China manufacturing facility has ... successful clearance of the Warning Letter related to our ... measure of the progress we have made in our ongoing ...
(Date:6/9/2017)... and INDIANAPOLIS , June 9, 2017 ... with diabetes. In a further effort to help spread ... by this condition, the International Diabetes Federation (IDF) and ... have come together for the second phase of the ... programme (BRIDGES 2), reaffirming their commitment to helping people ...
Breaking Medicine Technology: